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Abstract
Background
Pancreatic adenocarcinoma is a lethal disease with 5-year survival of less than 5%. 5-fluo-
rouracil (5-FU) is a principal first-line therapy, but treatment only extends survival modestly
and is seldom curative. Drug resistance and disease recurrence is typical and there is a
pressing need to overcome this. To investigate acquired 5-FU resistance in pancreatic ade-
nocarcinoma, we established chemoresistant monoclonal cell lines from the Panc 03.27
cell line by long-term exposure to increasing doses of 5-FU.
Results
5-FU-resistant cell lines exhibited increased expression of markers associated with multi-
drug resistance explaining their reduced sensitivity to 5-FU. In addition, 5-FU-resistant cell
lines showed alterations typical for an epithelial-to-mesenchymal transition (EMT), including
upregulation of mesenchymal markers and increased invasiveness. Microarray analysis re-
vealed the L1CAM pathway as one of the most upregulated pathways in the chemoresistant
clones, and a significant upregulation of L1CAM was seen on the RNA and protein level. In
pancreatic cancer, expression of L1CAM is associated with a chemoresistant and migratory
phenotype. Using esiRNA targeting L1CAM, or by blocking the extracellular part of L1CAM
with antibodies, we show that the increased invasiveness observed in the chemoresistant
cells functionally depends on L1CAM. Using esiRNA targeting β-catenin and/or Slug, we
demonstrate that in the chemoresistant cell lines, L1CAM expression depends on Slug rath-
er than β-catenin.
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Conclusion
Our findings establish Slug-induced L1CAM expression as a mediator of a chemoresistant
and migratory phenotype in pancreatic adenocarcinoma cells.
Introduction
Pancreatic adenocarcinoma is an extremely deadly disease. The early course of the disease is
often asymptomatic leading to only 8% of cases being diagnosed at this stage. The outlook for
late-stage adenocarcinoma patients is bleak, with only 20% of patients being candidates for sur-
gery (due to late diagnosis/tumor metastasis), resulting in a 5-year survival of less than 5% [1].
Current treatment options available may extend survival and relieve symptoms in patients, but
are not curative in most cases.
5-Fluorouracil (5-FU) has for a long time been an established form of chemotherapy for
pancreatic adenocarcinoma, together with the drug gemcitabine [2]. However, inherent (de
novo) and acquired resistance are major obstacles for the success of 5-FU based chemotherapy
in pancreas adenocarcinoma and other tumors [3]. Acquired drug resistance, which develops
during treatment, is often manifested by several resistant mechanism and is therefore therapeu-
tically difficult to reverse.
5-FU decreases the biosynthesis of pyrimidine nucleotides by inhibiting thymidylate
synthase (TS), an enzyme that catalyzes the rate-limiting step in DNA synthesis [4]. Although
the mechanisms of resistance to 5-FU remains unclear, several reports have linked chemoresis-
tance in various solid tumor cell lines to epithelial-to-mesenchymal transition (EMT) [5–8].
EMT is a fundamental embryological process characterized by alterations in morphology, cel-
lular architecture, signaling and adhesion leading to a migratory phenotype [9]. When EMT
occurs in tumor cells, these cells lose their epithelial features and acquire a more invasive and
migratory phenotype leading to augmented metastatic potential. Molecular markers for EMT
include increased expression of vimentin and N-cadherin and increased expression of tran-
scription factors that repress E-cadherin expression, including Twist, Snail, and Slug [10].
The L1 cell adhesion molecule (L1CAM) is a highly conserved transmembrane glycoprotein
of the immunoglobulin superfamily that was first identified to play a part in the development
and regeneration of neuronal tissue [11]. L1CAM expression has been observed in a number of
cancer cell lines and tissues, and high L1CAM expression is often associated with poor progno-
sis and short survival times [12]. L1CAM has been linked to EMT in several different cancer
types, including pancreatic cancer [13–18]. In particular, L1CAM has been associated with a
chemoresistant and migratory phenotype in pancreatic ductal adenocarcinoma (PDAC) [19–
21]. To investigate the mechanisms involved in the acquisition of 5-FU resistance, we estab-
lished 5-FU-resistant clones from the pancreatic adenocarcinoma cell line Panc 03.27, and sub-
jected the cell lines to functional tests and microarray analysis. The chemoresistant Panc 03.27
cells underwent phenotypic changes consistent with an EMT, and the expression of EMT-relat-
ed markers, particularly L1CAM, increased substantially. Knockdown studies showed that the
L1CAM expression in the 5-FU-resistant clones was dependent on the transcription factor
Slug but not on β-catenin, and knockdown of L1CAM confirmed a functional link between
L1CAM and the proliferative and invasive potential of the chemoresistant Panc 03.27 clones.
Knockdown studies further showed that L1CAMmoderately protected chemoresistant B1V
cells from apoptosis induced by 5-FU. Our findings provide further insight into the molecular
mechanisms leading to a chemoresistant and migratory phenotype in pancreatic cancer cells
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and highlight the importance of addressing Slug-induced L1CAM expression in recurrent
PDAC.
Results
Development of 5-FU-resistant clones
Panc 03.27 5-FU-resistant cell lines were generated by continuous exposure of the tumor cells
to 5-FU over a 6 month period, starting at 0.5 μg/ml 5-FU and increased to 1 μg/ml over time.
To verify the dose dependent chemoresistance of the obtained clones, a dose curve was run to a
range of 5-FU concentrations (0.5–10 μg/ml) over a 6 day period. As expected, clones that were
grown without 5-FU selection (named Nt and Nw) were sensitive to all concentrations of
5-FU. In the chemoresistant clones B1Q and B1V normal growth was seen with doses up to
1 μg/ml 5-FU, while the higher concentrations of 5-FU (5–10 μg/ml) still inhibited growth
(Fig 1A).
5-FU-resistant clones display resistance mechanisms
5-FU sensitivity has been shown to be inversely related to the level of thymidine synthase (TS)
protein in cancer cells, and 5-FU-resistant tumors commonly express high levels of TS protein
[22,23]. High expression of TS in cancer tissue is an indicator of poor prognosis for 5-FU-
based chemotherapy for colorectal cancer patients [24]. The protein level of TS was analyzed in
all four clones. TS was drastically increased in the chemoresistant clones B1Q and B1V, as
shown by Western blot analysis (Fig 1B). Using taqman RT-PCR, we next analyzed the RNA
levels of efflux pumps associated with 5-FU- and multidrug resistance [25,26]. We observed a
statistically relevant increase in the expression of the efflux pumps ABCB1 (MDR1) and
ABCC5 (MRP5) in the chemoresistant clones as compared to the chemosensitive clones (Fig
1C). The level of survivin was also greatly increased in the chemoresistant clones as assessed by
Western blotting (Fig 1D). Survivin is an inhibitor of apoptosis expressed in the G2/M phase of
the cell cycle and overexpression of survivin is linked to resistance to apoptotic stimuli induced
by chemotherapeutic drugs [27,28].
5-FU-resistant clones display morphological changes that are
associated with EMT
When the morphology of the 5-FU-resistant clones was compared to the sensitive clones, the
former displayed a more mesenchymal-like phenotype, with cell scattering and increased for-
mation of pseudopodia, while the sensitive clones display a tightly packed epithelial morpholo-
gy (Fig 2A). The 5-FU-resistant cells appeared larger and more stretched out than the sensitive
cells. The mesenchymal-like phenotype, which was maintained for over 30 passages, is in line
with previous observations of drug-induced chemoresistance in cell lines [29,30].
Important hallmarks of EMT are a downregulation of the epithelial marker E-cadherin ac-
companied by an upregulation of N-cadherin and vimentin [9]. Accordingly, the chemoresis-
tant clones showed an increase in vimentin (Fig 2B and 2E) and N-cadherin (Fig 2D and 2G)
on both protein and RNA levels, and a downregulation of E-cadherin (Fig 2C and 2F). Cytoker-
atin 19 (CK19) is an intermediate filament that is in part responsible for the structural integrity
of cells. Various cytoskeletal modifications within a cell are associated with malignant transfor-
mation, and a loss of CK19 has been associated with EMT [31] and multidrug resistance [32].
When the Nt, Nw, B1Q and B1V clones were analyzed for the expression of CK19 by immuno-
cytochemistry and Western blot, a massive reduction of CK19 was found in the chemoresistant
clones as compared to the 5-FU sensitive clones (Fig 2H and 2I). To evaluate if the changed
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morphology that was observed in the chemoresistant clones was functionally significant, we ex-
amined the invasive properties of the clones using a matrigel invasion assay (Fig 2J and 2K).
Chemoresistant clones B1Q and B1V were 4 to 6 times more invasive than the two chemosen-
sitive clones Nt and Nw.
Fig 1. 5-FU-resistant clones display resistancemechanisms. (A) The chemosensitive (Nt, Nw) and
resistant (B1Q and B1V) cell lines were treated with 0–10 μg/ml 5-FU) over 6 days. Graph displays growth vs.
days of exposure. (B) Western blot showing the levels of Thymidylate Synthase (TS) in the chemosensitive
and the chemoresistant cell lines. (C) RNA levels (relative quantity) of ABCB1 (MDR1) and ABCC5 as
measured by RT-PCR. (D) Western blot showing the levels of survivin in the chemosensitive and the
chemoresistant cell lines. Error bars represent standard deviation. Statistically significant difference between
the chemosensitive and the chemoresistant clones (P <0.05) is indicated by *.
doi:10.1371/journal.pone.0123684.g001
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Fig 2. 5-FU-resistant clones display morphological changes that are associated with EMT. (A) Phase contrast photos showing cell morphology of
normal (Nw, Nt) and chemoresistant clones (B1Q, B1V), 40x. (B-D) RNA levels (relative quantity) of vimentin, E-cadherin, and N-cadherin, as measured by
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L1CAM is upregulated in the 5-FU-resistant cells
In order to establish a more exhaustive molecular profile between the sensitive and non-sensi-
tive cell lines, we performed microarray analysis including the 5-FU resistant cell line B1V and
the chemosensitive clone Nt. 607 genes were considered as they presented with log2
change> 1 (S1 Fig). 319 genes were found to be upregulated and 288 genes were downregu-
lated at least 2-fold in B1V compared to Nt (P<0.05) (S1 and S2 Tables, respectively). Gene
Ontology analysis of the 319 upregulated genes revealed that the L1CAM interaction pathway
was one of the most upregulated pathways in the chemosresistant clones, together with cyto-
kine and inflammatory responses (Fig 3A). L1CAM itself was upregulated 4 times in the B1V
cells compared to the Nt cells. Hallmarks of Wnt signaling and pluripotency, apoptosis, seroto-
nin transporter activity, monoamine transport and glycogen metabolism were also found to be
upregulated in the B1V chemoresistant cell line (Fig 3A and S1 Table).
The increase in L1CAM in the chemoresistant clones was confirmed by real-time PCR
(P<0.05) andWestern blot analysis (Fig 3B and 3C, respectively). Furthermore, flow cytometric
analysis using a PE-conjugated anti-L1CAM antibody showed enrichment of L1CAM positive
cells in the B1Q and B1V cell lines (Fig 3D). In support of this observation, immunohistochem-
istry revealed a distinct L1CAM expression in the membrane of the chemoresistant clones B1Q
and B1V but not in the chemosensitive cells Nt and Nw (Fig 3E). A proportion of the chemore-
sistant cells also exhibited nuclear L1CAM immunoreactivity.
L1CAM is involved in proliferation and invasiveness of the 5-FU-
resistant clones, and moderately protects the chemoresistant cells from
5-FU-induced apoptosis
EMT has been associated with an increased invasiveness of tumor cells [33], and previously
published reports showed that L1CAM triggers cell migration and invasion in several tumor
types [15,18,34]. To investigate whether the upregulation of L1CAM is involved in the in-
creased invasion potential of the chemoresistant cells, the expression of L1CAM was knocked
down using esiRNA. esiRNA are endoribonuclease-prepared siRNA pools comprised of a het-
erogeneous mixture of siRNAs that all target the same mRNA sequence. esiRNA treatment
dramatically reduced the protein level of L1CAM in the chemoresistant cell lines B1Q and B1V
(Fig 4A), compared to cells transfected with control esiRNA (targeting EGFP). When assayed
for invasiveness in a matrigel invasion chamber the number of invasive cells after L1CAM
knockdown was significantly lower compared to the negative control after 24 h invasion (Fig
4B). To further assess the relationship between the invasiveness of the chemoresistant clones
and L1CAM expression, cells were treated with either an antibody targeting the extracellular
part of L1CAM (clone UJ127.11), or a mouse isotype control antibody, prior to an invasion
assay experiment (invasion assay times were increased to 48 hours). Our results show that
treating B1Q and B1V cells with the L1CAM antibody significantly reduced their invasiveness
compared to treatment with the control antibody. By contrast, treating chemosensitive Nt and
Nw cells with L1CAM antibody had no effect on invasiveness (Fig 4C).
RT-PCR. Error bars represent standard deviation. Statistically significant difference between the chemosensitive and the chemoresistant clones (P <0.05) is
indicated by *. (E-G) Western blot and immunostain showing the levels of vimentin, E-cadherin, and N-cadherin, in the chemosensitive (Nt, Nw) and the
chemoresistant (B1Q, B1V) cell lines. (H) Immunostain and (I) Western blot showing levels of CD19 in the chemosensitive and the chemoresistant cell lines.
(J) Graph displaying the results of 24 hour invasion assays performed on the clones, with phase contrast images (20x) showing representative areas of
invading cells stained with crystal violet stain (K). Assay was performed three times. Statistically significant difference between the chemosensitive and the
chemoresistant clones (P <0.05) is indicated by *.
doi:10.1371/journal.pone.0123684.g002
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Overexpression of L1CAM has been shown to promote tumor cell proliferation, and accord-
ingly, inhibition of L1CAM expression or function can suppress proliferation [35–37]. To in-
vestigate whether knockdown of L1CAM had an influence on cell growth in the
chemoresistant cells, we performed in vitro proliferation assays. All cell lines were subjected to
L1CAM and control esiRNA treatment, and the percentage confluence was measured over
time by an IncuCyte automated reader (Fig 4D). Measurements started 24 hours after esiRNA
transfection. We have previously observed that the effect of esiRNA knockdown on protein
level gradually diminishes after 72 hours (results not shown), but to obtain a proper growth
curve the experiments were run for at least 96 hours post transfection. The growth curves
showed no effect of the esiRNA treatment targeting L1CAM on the chemosensitive cell lines
Nt and Nw. However, the chemoresistant cell lines B1Q and B1V displayed significantly re-
duced growth following L1CAM knockdown (Fig 4D) demonstrating that L1CAM expression
is involved in cell proliferation of the chemoresistant cells.
When the anti-L1CAM antibody that inhibited invasion in the chemoresistant cells was
added to in vitro proliferation assays, we could not see any difference in percentage cell conflu-
ence between cells treated with the antibody compared to cells treated with the control anti-
body. This was performed on all four cell lines.
L1CAM has been shown to play a role in the mediation of chemoresistance against gemcita-
bine and etoposide in PDAC cell lines [38]. To assess whether the L1CAM was involved in me-
diating resistance to 5-FU in the chemoresistant Panc 03.27 cell lines, Annexin V flow
cytometric assays were carried out in Nt and B1V cells 72 hours after cells were treated with
L1CAM or control esiRNA in the presence and absence of 1 μg/ml 5-FU. As expected, Nt cells
treated with a control esiRNA showed a significant shift towards Annexin V positive cells after
being exposed to 5-FU (from 0.87% to 18.32%). In contrast, control treated B1V cells did only
show a slight increase (from 1.19% to 2.22%) in Annexin V positive cells in response to 5-FU
treatment (Fig 4E and 4F). Knockdown of L1CAM did not significantly alter the rates of apo-
ptosis in the chemosensitive cell line Nt, either in the presence or absence of 5-FU treatment
when compared to the ctrl knockdown (Fig 4E). However, knockdown of L1CAM increased
percentage Annexin V positive cells, both with or without 5-FU treatment. Thus, L1CAM ap-
pears to moderately protect chemoresistant B1V cells from apoptosis in the absence of 5-FU,
and more so in the presence of 5-FU (Fig 4F).
Transcriptional regulation of L1CAM depends on Slug, but not on β-
catenin
Previous studies have implicated both Slug and β-catenin in the transcriptional regulation of
L1CAM [14,39–41]. Slug is a transcriptional factor that is involved in EMT and invasiveness in
pancreatic cancer [34,42]. L1CAM is considered to be a target of β-catenin, the key mediator of
canonical Wnt signaling with a role in the contextual regulation of proliferation, decision
points between ‘stemness’ and differentiation, cellular metabolism and EMT [39,43]. Since the
microarray analysis revealed an upregulation of components that may contribute to canonical
Wnt signaling in the chemoresistant cells (Fig 3A), the levels of β-catenin in the chemosensitive
and chemoresistant cell lines were investigated. RNA levels of β-catenin were significantly
Fig 3. L1CAM is upregulated in the 5-FU-resistant cells. (A) Gene Ontology analysis of 319 genes upregulated in the B1V clone compared to the Nt clone
of the Panc 03.27 cell line. (B) RNA levels (relative quantity) of L1CAM in the chemosensitive (Nt, Nw) and the chemoresistant (B1Q, B1V) cell lines, as
measured by RT-PCR. Error bars represent standard deviation. Statistically significant difference between the chemosensitive and the chemoresistant
clones (P <0.05) is indicated by *. (C)Western blot showing levels of L1CAM in all cell lines. (D) Flow cytometric analysis using anti L1CAM-PE antibody on
all cell lines. Unstained cells are shown in grey and antibody-stained cells are shown in black. (E) Immunostain of L1CAM. Increased membrane localization
of L1CAM can be seen in the of the chemoresistant lines (B1Q, B1V). Images are taken with 40x magnification.
doi:10.1371/journal.pone.0123684.g003
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Fig 4. L1CAM is involved in proliferation and invasiveness of the 5-FU-resistant clones. (A) Control western blot showing the levels of L1CAM following
transfection with esiRNA targeting L1CAM or control esiRNA, as described inMaterials and methods. Actin is used as loading control. (B) Graph displaying
number of invading cells (24 h invasion assays) following transfection with esiRNA targeting L1CAM or control esiRNA. Experiments were performed twice
with similar results. Representative results are shown. (C) Graph displaying numbers of invading cells (48 h invasion assays) of cells treated with 2 μg/ml
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increased (P< 0.05) in the chemoresistant clones (Fig 5A), but in the microarray the increase
was less than two-fold and thus did not appear on the list of genes that were more than two-
fold upregulated in the microarray (S1 Table). Western blots show no difference in the levels of
total β-catenin protein between the chemosensitive and the chemoresistant cells, neither in the
cytoplasm nor in the nucleus. (Fig 5A). Active β-catenin levels, as measured by an antibody de-
tecting only active (unphosphorylated) protein, were not changed either (results not shown).
Slug did not show alterations in the microarray, which was also confirmed by RT-PCR (Fig
5B). However, a Western blot analysis showed a clear upregulation of Slug protein levels in
both chemoresistant cell lines compared to the chemosensitive cell lines (Fig 5B). To test the
impact of β-catenin and Slug on the expression of L1CAM, both β-catenin and Slug were tar-
geted by esiRNA. Knockdown of Slug, but not β-catenin, lead to a decrease in L1CAM protein
levels (Fig 5C and 5D).When Slug and β-catenin were knocked down simultaneously in the
chemoresistant cells, no further reduction in the levels of L1CAM was observed (results not
shown).
When assayed for invasiveness after Slug knockdown, B1Q and B1V cells displayed reduced
invasiveness compared to the esiRNA control cells (24 h invasion; Fig 5E), in a similar manner
to what was seen with knockdown of L1CAM (Fig 4B). Pretreatment with L1CAM antibody in
addition to Slug knockdown did not further reduce the invasive ability of the chemoresistant
lines (Fig 5E). Although the acquisition of 5-FU-resistance induced a multitude of changes in
the Panc 03.27 pancreas adenocarcinoma cells, we identified L1CAM and its regulation
through Slug as a major mediator of an invasive phenotype and acquired chemoresistance, and
as a potential therapeutic target.
Discussion
5-FU was the systemic therapy of choice for advanced pancreatic cancer for many years, but in
the late 90’s it was shown that the drug gemcitabine was superior to 5-FU in controlling dis-
ease-related symptoms [44]. However, 5-FU is still a recommended treatment option for pan-
creatic cancer today [45], and several recent studies have demonstrated a valuable role for
5-FU in combined treatment protocols compared with single gemcitabine chemotherapy
[46,47].
Resistance to chemotherapeutic drugs is a major cause of treatment failure and poor prog-
nosis in pancreatic cancer. In this study we have shown that the pancreatic cancer cell line
Panc 03.27 subjected to long-term exposure to 5-FU developed resistance and acquired proto-
typical molecular features including upregulation of thymidylate synthase, survivin, and drug
pumps. Further, we demonstrated that the chemoresistant cells became more mesenchymal-
like and underwent EMT-related changes, including loss of epithelial markers (E-cadherin and
CK19) and enhanced expression of the mesenchymal markers vimentin and N-cadherin, and
the transcriptional factor Slug. We showed an upregulation of L1CAM in the 5-FU-resistant
cells, which is in line with previous findings that support the hypothesis that L1CAM is upregu-
lated by cancer cells as a part of the EMT process [13–18]. We were further able to link
L1CAM to the process of EMT by demonstrating that the increased invasiveness of the che-
moresistant cells was dependent on L1CAM, and that expression of L1CAM was dependent on
anti-L1CAM antibody (clone UJ127.11) or control isotype antibody for 1 h at room temperature before they were added to the invasion assay plate. (D)
Incucyte growth curves (96 hours) of all cell lines following transfection with esiRNA targeting L1CAM or control esiRNA. The experiment was performed in
triplicates. (E) The chemosensitive cell line Nt and the chemoresistant cell line B1V (F) were treated with 1 ug/ml 5-FU for 72 h following transfection with
esiRNA targeting L1CAM or control, and Annexin V flow cytometric assays were performed. Each assay was repeated twice with similar results. Percentage
in the graphs shows Annexin V-positive cells.
doi:10.1371/journal.pone.0123684.g004
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Slug. In line with this observation, Gavert et al. showed that stimulation of pancreatic ductal
epithelial cells with TGF-β1 led to the acquisition of a spindle-shaped cell morphology and
Fig 5. Transcriptional regulation of L1CAM depends on Slug, but not β-catenin. (A) RNA levels (relative quantity, RT-PCR) and western blot showing
protein levels of β-catenin in the chemosensitive (Nt, Nw) and the chemoresistant (B1Q, B1V) cell lines. (B) RNA levels (relative quantity, RT-PCR) and
western blot showing protein levels of Slug in the chemosensitive (Nt, Nw) and the chemoresistant (B1Q, B1V) cell lines. Protein levels of Slug in the western
blot were quantified using Image Studio Lite (version 3.1.4) (normalized against loading controls). (C) Levels of L1CAM following transfection with esiRNA
targeting β-catenin or control esiRNA. (D) Levels of L1CAM following transfection with esiRNA targeting Slug or control esiRNA. Quantification of band
intensities can be seen in the lower panels in (C) and (D). (E) Graph displaying number of invading cells (24 h invasion assays) following transfection with
esiRNA targeting Slug or control esiRNA, in combination with 2 μg/ml anti-L1CAM antibody (UJ127.11) or control isotype antibody for 1 h at room
temperature. Experiments were performed twice with similar results. Representative results are shown. Actin is used as loading control in all western blots.
Error bars in the RT-PCR graphs represent standard deviation. Statistically significant differences (P <0.05) between the chemosensitive and the
chemoresistant clones are indicated by *.
doi:10.1371/journal.pone.0123684.g005
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upregulation of mesenchymal proteins and L1CAM expression, which was dependent on JNK-
mediated activation of Slug [40].
In the breast carcinoma cell line MCF7, upregulation of L1CAM has been shown to lead to
disruption of E-cadherin-containing adherens junctions and thereby to increased transcrip-
tional activity of β-catenin [48]. Activation of β-catenin contributed to sustained L1CAM ex-
pression and enhanced cell motility [48], which is in line with other evidence showing that
L1CAM is a target of β-catenin signaling [39]. However, our results did not show altered pro-
tein expression or localization of β-catenin in the chemoresistant cells, and more importantly,
knockdown of β-catenin did not reduce levels of L1CAM, indicating that L1CAM expression
was not regulated by β-catenin in these cells. Our results are thus in line with findings by Pfeifer
et al. showing in endometrial carcinoma that Slug, and not β-catenin, is responsible for upregu-
lation of L1CAM [41].
Overexpression of L1CAM has been shown to promote tumor cell proliferation, and inhibi-
tion of L1CAM expression or function can suppress proliferation [35–37]. Knockdown of
L1CAM reduced proliferation in the chemoresistant Panc 03.27 cell lines (Fig 4D). This reduc-
tion in growth was not seen in the chemosensitive cell lines not expressing L1CAM. Our results
point towards a specific role for L1CAM in the proliferation of 5-FU-resistant pancreatic can-
cer cells. Further work is needed to understand the effect of L1CAM on proliferation, however,
other reports point towards a link to the Erk1/2 and the Akt-pathways, which both are known
to accelerate proliferation and growth of tumor cells [35,37,49,50]. Furthermore, the reduced
proliferation seen for the chemoresistant clones following L1CAM knockdown in Fig 4D
can partly be a result of the slight increase in apoptosis seen in Fig 4F, following L1CAM
knockdown.
Interestingly, the increased invasiveness displayed by our chemoresistant clones was re-
duced when L1CAM was knocked down, or when the extracellular part of L1CAM was blocked
with an antibody. Increased invasiveness through upregulation of L1CAM is possibly one of
many regulations downstream of Slug following induction of EMT.
There are some contradictory reports on the role L1CAM plays in the process of EMT. For
instance, Gavert et al. recently showed that L1CAMmediated metastasis of colon cancer cells
was dispensable for EMT induction and an altered expression of epithelial and mesenchymal
marker proteins [51]. Further studies are required to elaborate whether upregulation of
L1CAM is part of the EMT or even the inducing event. L1CAMmight not be an EMT-media-
tor itself, but appears to be regulated by EMT-induced Slug, and once expressed it seems to
drive invasion.
L1CAM has been shown to be involved in the mediation of chemoresistance against gemci-
tabine and etoposide in PDAC cell lines [38]. We investigated whether knockdown of L1CAM
reduced the acquired resistance to 5-FU displayed by the cell line B1V. In our hands, L1CAM
appeared to moderately protect cells from apoptosis in the absence of 5-FU, and more so in the
presence of 5-FU.
Further studies are planned to investigate whether treatment with anti-L1CAM antibodies
will reduce growth or metastasis of our 5-FU-resistant pancreatic cancer cell lines in vivo. The
finding that pancreatic cancer cells with acquired resistance to 5-FU show increased expression
of L1CAM, in addition to the distinction of L1CAM presence in cancerous vs. normal tissues
[52], makes us hopeful that targeting of L1CAM with therapeutic antibodies and/or in combi-
nation with 5-FU could potentially benefit selected patients with refractory pancreatic tumors.
Our findings provide further insight into the molecular mechanisms leading to a chemoresis-
tant and migratory phenotype in pancreatic cancer cells and highlight the importance of ad-
dressing Slug-induced L1CAM expression in recurrent pancreatic cancer.
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Materials and Methods
Cells and culture conditions
Panc 03.27 pancreatic adenocarcinoma cells were obtained from ATCC (CRL-2549) and cul-
tured in RPMI medium (R8758, Sigma-Aldrich) containing 10% FBS (16000–044, Invitrogen)
and penicillin/streptomycin (P/S, 17-603E, BioWhittaker), and 500 μl ITS (I3146, Sigma-Al-
drich) at 37°C in a humidified atmosphere of 5% CO2. Cell lines were detached using Accutase
(L11–007, PAA).
5-FU-resistant cell line creation and clone isolation
Panc 03.27 5-FU-resistant cell lines were generated by continuous exposure of the tumor cells
to 5-Fluorouracil (5-FU, F6627, Sigma-Aldrich) over a 6 month period. 5-FU was dissolved in
DMSO (D8418, Sigma-Aldrich). Incubation began with 0.5 μg/ml 5-FU and increased to 1 μg/
ml over time. After stable, proliferating lines resistant to 1 μg/ml 5-FU were created, clones
were selected through limited dilution and clones derived from single cells were isolated and
expanded over the next 3–4 months.
5-FU dose curve (proliferation assay)
Cells were plated at 1,500 cells per well in 96 well plates (Nunc) and allowed to attach over-
night. The following morning media was replaced with 200 μl 5-FU containing media in a
range from 0–10 μg/ml. The viability of the cells was determined by performing MTS assays ac-
cording to manufacturer’s protocol (G3582, CellTiter 96 AQueous Non-Radioactive Cell Prolif-
eration Assay (MTS), Promega), and absorbance at 490 nm was measured using an SLT
SPECTRA plate reader (Perkin Elmer, Waltham, Massachusetts, USA). One plate was read be-
fore addition of 5-FU to serve as the initial absorbance reading. Plates were then read daily
(once every 24 hours) for 6 days and growth was calculated by subtracting the background ab-
sorbance. Data represent means n = 6 for each data point.
Incucyte growth curves
24 hours after transfection with esiRNA, cells were detached using Accutase (L11–007, PAA)
and replated at 1,500 cells per well in 96-well plates (Nunc). The plates were imaged using an
IncuCyte FLR 20x (Essen BioScience, Ann Arbor, Michigan, USA), with phase contrast photos
taken every 4 hours for the duration of the experiment, and % confluence was given as output.
Graph in Fig 4D shows average percentage well coverage every 12 hours. Representative phase
contrast images from the IncuCyte were used in Fig 2A (20x objective; scale bar attached to
every image). Data represent means n = 6 for each data point.
Microarray hybridization and analysis
Microarray hybridizations (4 replicates per condition) were performed in the Norwegian Mi-
croarray and Sequencing Core Facility (Norwegian Microarray Consortium) at the Oslo Uni-
versity Hospital HF. First, 500 ng of total RNA was amplified and labeled using Illumina RNA
TotalPrep Amplification kit according to manufacturer’s instructions. 750 ng of biotin labeled
cRNA was hybridized to Illumina’s Human HT-12 v4 Expression BeadChip according to the
manufacturer's instructions. The probes on the Illumina chip are based on the content from
the National Center for Biotechnology Information RefSeq database (HumanHT-
12_V4_0_R2_15002873_B). The data were quantile normalized, and average of probe set sig-
nal per gene was used to calculated averages of signals across arrays in replicates.
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Hybridizations and differential expression was assessed by calculating fold change in the B1V
line versus the Nt line.
For ontology classifications, genes upregulated at least 2 fold in B1V versus the Nt cells were
fed into HOMER (Hypergeometric Optimization of Motif EnRichment) [53] sub scripts
findGO to retrieve enrichment calculated assuming cumulative hypergeometric distribution.
The gene ontology of biological processes according to Wiki pathways was used to determine
enriched pathways and only pathways with P< 0.05 were considered. (Microarray data can be
found in GEOarchive, accession number GSE58386.)
RT-PCR
Total RNA was isolated using the GeneElute miniprep kit (Sigma) following the manufacturer's
instructions. cDNA was synthesized using the SuperScript VILO kit (11754050, Life Technolo-
gies), and real-time PCR was carried out using TaqMan gene expression master mix (4369016,
Life Technologies) according to the manufacturer's instructions on a StepOnePlus cycler (Life
Technologies, Waltham, Massachusetts, USA). GAPDH was used to normalize the amount of
cDNA in each sample and to guarantee the comparability of the calculated mRNA expression
in all samples analyzed. In all real-time PCR graphs in Fig 2, the sample Nt is set to 1, and all
samples are set relative to Nt. Error bars represent standard deviation. Statistically significant
difference between Nt and B1V (P<0.05) is indicated by . To assess whether the real-time
PCR results were significantly different we used the two-sided Students t-test by Sigma plot
2001. Data represent Means ± SD; n3.
Probes were ordered from Life Technologies and were as follows;
ABCB1-Hs00184500_m1
ABCC5-Hs00981087_m1
CTNNB1-Hs00355049_m1
GAPDH-Hs02758991_g1
Vimentin-Hs00185584_m1
CDH1/Ecadherin-Hs01023894_m1
CDH2/Ncadherin- Hs00983056_m1
L1CAM- Hs01109748_m1
SNAI2- Hs00950344_m1
Invasion assay
BD BioCoat matrigel invasion chamber 24-well plates; growth factor reduced; 8.0 μm pore size
(354483, BD Biosciences) were used in the experiment as such; 25,000 cells (Fig 2J); 20,000
cells (Fig 4B and 4C); or 15 000 cells (Fig 5E) were plated in the top chamber in 500 μl of media
containing 1% FBS and P/S. The bottom wells contained 750 μl of RPMI with 20% FBS. The
cells were allowed to invade for 24 hours (Figs 2J, 4B, and 5E) or 48 (Fig 4C) hours, then the
non-invading cells were scraped from the upper surface of the membrane with a cotton swab,
and the cells on the lower side were stained with 0.02% crystal violet (HT90132, Sigma-Al-
drich) in formaldehyde (F8775, Sigma-Aldrich). The number of invading cells was counted
through the entire surface area (about 9 microscopic fields at 10x). In the antibody blocking ex-
periment, cells were incubated in RPMI medium containing 1% FBS and P/S and either 2 μg/
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ml mouse anti-L1CAM antibody (UJ127.11, Sigma), or 2 μg/ml mouse IgG isotype control an-
tibody (sc-2025, Santa Cruz) for 1 hour at 4°C, before added to invasion assay. Antibody was
also present during the invasion assay. Data represent Means ±SD; n = 3 for each data point.
Each assay was run at least twice.
Western blot
Total cell extracts were made by adding cold TM buffer containing protease inhibitors (Total
protein extraction kit, 2140, Millipore) to 80% confluent T25 flasks (136196, Nunc). Flasks
were incubated on ice for 30 minutes and cells were collected using cell scrapers from Starstedt
into 1.5 ml Eppendorf tubes, followed by centrifugation for 15 minutes at 13,000 rpm. Superna-
tant was transferred to another tube and protein concentration was measured using Bradford
Assay (500–0205, Bio-Rad). Cytoplasmic and nuclear extracts: cells were detached using Accu-
tase (L11–007, PAA), washed 1x in RPMI and 2x in PBS, and isolated using the Thermo
NE-PER Nuclear and Cytoplasmic Extraction kit (78833, Thermo Scientific) per manufactur-
er’s instructions. Protein concentration was measured using Bradford assay. Protein samples
were loaded on to gels (Novex Bis-Tris or Tris-Acetate gels, Life Technologies) with PageRuler
prestained protein ladder (26616, Fermentas) and run in Novex electrophoresis chambers (Life
technologies). Proteins were transferred to nitrocellulose membranes (LC2000, Novex, Life
Technologies), blocked with 5% milk (A0830,0500, AppliChem), 0.05% tween-20 in TBS (09-
7510-100, Medicago) for 1 hour, and stained with primary (4°C overnight with rocking in 5%
milk, 0.05% tween-20 in TBS) and secondary antibodies (1 hour at room temperature with
rocking in 5% milk, 0.1% tween-20 in TBS). Primary antibodies used; monoclonal mouse anti-
active β-catenin (1:2000, 05–665, Millipore), monoclonal rabbit anti-Actin (1:2000, A5441,
Sigma-Aldrich), monoclonal mouse anti-β-catenin (1:5000, 610154, BD Transduction Labora-
tories), polyclonal rabbit anti-CK19 (1 μg/ml, ab15463, Abcam), polyclonal rabbit anti-Lamin
B1 (0.1 μg/ml, ab16048, Abcam), monoclonal rabbit anti-TS (1:1000, ab108995, Abcam), poly-
clonal goat anti-SLUG (1:100, sc-10436, Santa Cruz), monoclonal mouse anti-L1CAM (1:1000,
L4543 (UJ127.11), Sigma-Aldrich), polyclonal rabbit anti-E-cadherin (1:500, ab15148,
Abcam), monoclonal mouse anti-vimentin (1:1000, ab8978, Abcam), and polyclonal rabbit
anti-survivin (1:1000, ab24479, Abcam). Secondary antibodies used are goat anti-mouse HRP
or donkey anti-rabbit HRP (both 1:10000, sc-2005 and sc-2313, Santa Cruz). Bands were visu-
alized using ECL plus (RPN2236, Amersham) on Amersham Hyperfilm (28906836, Amer-
sham). Image Studio Lite (version 3.1.4) was used to quantify bands (normalized against
loading controls).
Flow cytometric analysis of L1CAM expression
To investigate cell surface expression of L1CAM on the Panc 03.27 cell lines, flow cytometric
analysis with PE-conjugated monoclonal anti-L1CAM antibody was performed (1:100,
ab95694, Abcam). Cell lines were detached using Accutase (L11–007, PAA), washed 1x in
RPMI and 2x in PBS, before they were resuspended in PBS containing anti-L1CAM-PE anti-
body, diluted 1:100. Cells were incubated at room temperature for 1 hour, before they were
washed twice in PBS after antibody incubation. Acquisition of data was performed using an
EasyCyte flow cytometer (GuavaTechnologies). A minimum of 5,000 cells were acquired per
sample and exclusion of non-viable cells and debris was based on lower forward scatter and
side scatter properties. Data analysis was performed using Flowing Software (Version 2.5.1).
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Annexin V Assay (Flow cytometry)
To perform Annexin V assay on the Panc 03.27 cell lines, Annexin V FITC Assay (BD Biosci-
ences) was used. Following esiRNA transfection and/or 5-FU treatment, cell lines were de-
tached using Accutase, and spun at 300 rpm for 5 minutes together with used medium to
collect released/dead cells. Medium was removed, and Annexin V was added to cells according
to product protocol. Acquisition of data was performed using an EasyCyte flow cytometer
(GuavaTechnologies). Exclusion of non-viable cells and debris was based on lower forward
scatter and side scatter properties. Data analysis was performed using Flowing Software (Ver-
sion 2.5.1).
Immunofluorescence
Cells were plated at 20,000 cells/well on coverslips in 24 well plates and allowed to attach over-
night. Wells were fixed, permeabilized, and blocked as described previously [54]. Cells stained
on cover slips were mounted on slides using Fluorescence Mounting Medium (S3023, DAKO).
The coverslips were then incubated for 16 hours at 4°C with polyclonal rabbit anti-CK19
(10 μg/ml, ab15463, Abcam) or polyclonal rabbit anti-N-cadherin (1:100, ab76057, Abcam).
Alexa Fluor 594 polyclonal goat anti-rabbit (1:700, A-11012, Life Technologies) was used as a
secondary antibody in 1% BSA (A2153, Sigma-Aldrich) in PBS for 1 hour at room temperature.
For L1CAM, monoclonal anti-L1CAM-PE (1:50, ab95694, Abcam) was used. Nuclei were
counterstained with DAPI (1 μg/ml, 10236276001, Roche,), in PBS for 5 minutes at room tem-
perature. Images were obtained using an Axiovert 200M fluorescence microscope (Zeiss Axio-
vert 200 M, Carl Zeiss MicroImaging GmbH, Jena, Germany) with CCD camera (Zeiss
Axiocam HR), using Axiovision software. All images are taken with 40x magnification.
esiRNA knockdown of β-catenin, L1CAM, and Slug
300,000 cells per well were plated in 6-well plates and allowed to attach overnight in an incuba-
tor at 37°C, and with 5% CO2. The following morning, 30 nM of MISSION esiRNA targeting
human CTNNB1 (β-catenin, EHU139421), human L1CAM (EHU100991), or human SNAI2
(Slug, EHU048191) or MISSION esiRNA EGFP (EHUEGFP) as ctrl (all from Sigma) per well
was transfected using Lipofectamine 2000 (11668–019, Life Technologies), as per instructions.
Cells were then returned to the incubator for 24 hours. After 24 hours, the cells were either de-
tached and plated for further experiments (Immunostain, matrigel invasion assay) or left for
72 hours after change of medium (for RNA- and protein extractions).
Statistical analysis
To assess whether the data was significantly different we used the two-sided Student’s t- test by
Sigma plot 2001. A minimum significance level of P< 0.05 was used.
Supporting Information
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